Harrison.ai Medical Imaging AI — Annalise.ai and Franklin.ai Across 1,000+ Facilities

Harrison.ai is an Australian medical AI company that has developed deep learning products for radiologists (Annalise.ai) and pathologists (Franklin.ai). The company's AI tools help clinicians interpret medical imaging more accurately and quickly, addressing diagnostic workload pressures and radiologist shortages in healthcare systems globally. The company raised AUD 112 million (USD 112 million) in Series C funding in February 2025, bringing total funding to AUD 179 million, demonstrating strong investor confidence in Australian medical AI capabilities. Harrison.ai operates in 15 countries and has FDA clearance in 12 US markets, with its AI products deployed at over 1,000 healthcare facilities globally. The systems have supported over 6 million patient case analyses. The business model is Software-as-a-Service (SaaS), providing recurring revenue as the company expands into new geographies and clinical specialties. Harrison.ai combines technical AI capability with deep domain expertise in clinical workflows, regulatory navigation (TGA, FDA, and other international regulators), and customer success infrastructure — a combination that has proven essential for medical AI adoption. The company represents Australia's emerging strength in healthcare AI, an area where Australian research institutions (including CSIRO and university teaching hospitals) have built significant capabilities. The success of Harrison.ai in raising significant capital and achieving international regulatory clearances positions it as a flagship example of Australian AI companies solving specific, high-value clinical problems with global market potential.